Results 271 to 280 of about 545,624 (314)

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Cancer Cell, 2021
Hai-Yan Tu, Tangfeng Lv, Shun Lu
exaly  

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Cancer Cell, 2023
Thiruvengadam Arumugam, Chunhua Shi, Yukie Kashima   +2 more
exaly  

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer

Nature Reviews Clinical Oncology
F. Zhou, Haoyue Guo, Yang Xia, X. Le, Daniel Tan, Suresh S. Ramalingam, Caicun Zhou   +6 more
semanticscholar   +1 more source

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Nature Reviews Clinical Oncology, 2021
A. Friedlaender, V. Subbiah, A. Russo, G. Banna, U. Malapelle, C. Rolfo, A. Addeo   +6 more
semanticscholar   +1 more source

EGFR

1998
Tak W. Mak, Josef Penninger, John Roder, Janet Rossant, Mary Saunders   +4 more
openaire   +1 more source

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Journal of Thoracic Oncology, 2021
Edward Garon, John Heymach, Monique Nilsson   +2 more
exaly  

EGFR

1995
Klaus Seedorf, Axel Ullrich
openaire   +1 more source

EGFR

2006
openaire   +2 more sources

The eGFR Equation

American Journal of Health Promotion
openaire   +2 more sources

Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer

Cancer Cell, 2018
Tse-Ching Chen, Wei-Chien Huang, Ting Chen   +2 more
exaly